SEC Company Response from CymaBay Therapeutics, Inc. (CIK 0001042074) — Jul 9, 2020
CymaBay Therapeutics, Inc. (CIK 0001042074)
Date: July 9, 2020 · CIK: 0001042074 · Accession: 0001193125-20-190437
AI Filing Summary & Sentiment
File numbers found in text: 333-239670
Letter
Company Acceleration Request
CYMABAY THERAPEUTICS, INC.
7575 Gateway Blvd., Suite 110
Newark, CA 94560
(510) 293-8800
July 9, 2020
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Ada Sarmento
RE: CymaBay Therapeutics, Inc.
Registration Statement on Form S-3
File No. 333-239670
Ladies and Gentlemen:
CymaBay Therapeutics, Inc. hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on July 13, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
Very truly yours,
CymaBay Therapeutics, Inc.
Show Raw Text
CORRESP 1 filename1.htm Company Acceleration Request CYMABAY THERAPEUTICS, INC. 7575 Gateway Blvd., Suite 110 Newark, CA 94560 (510) 293-8800 July 9, 2020 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Ada Sarmento RE: CymaBay Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-239670 Ladies and Gentlemen: CymaBay Therapeutics, Inc. hereby requests that the Securities and Exchange Commission take appropriate action to cause the above-referenced Registration Statement on Form S-3 to become effective on July 13, 2020, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable. Very truly yours, CymaBay Therapeutics, Inc. By: /s/ Sujal Shah Sujal Shah President and Chief Executive Officer